Align Technology (ALGN) names Kevin Conroy chairman as C.R. Larkin retires
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Align Technology, Inc. announced a planned Board leadership transition. C. Raymond Larkin, Jr. will retire as Chairman of the Board effective July 1, 2026, after more than 20 years of service, and will remain on the Board and the Nominating and Governance Committee through December 31, 2026. His decision to step down from the Board is stated as not due to any disagreement with the company’s operations, policies, or practices.
The Board has appointed Kevin Conroy, an independent director since December 2023 and Chair of the Compensation and Human Capital Committee since January 2026, to become Chairman effective July 1, 2026. The company highlights his prior leadership at Exact Sciences and ongoing board role at Abbott Laboratories as relevant experience for Align’s next phase of growth and innovation in digital dentistry.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Chairman retirement effective date: July 1, 2026
Board service end date: December 31, 2026
Exact Sciences revenue under Conroy: $3.25 billion annual revenue
+5 more
8 metrics
Chairman retirement effective date
July 1, 2026
C. Raymond Larkin, Jr. retires as Chairman
Board service end date
December 31, 2026
Larkin remains a director until this date
Exact Sciences revenue under Conroy
$3.25 billion annual revenue
Exact Sciences revenue while Kevin Conroy led the company
Nellcor revenue under Larkin
Nearly $1 billion revenue
Nellcor Puritan Bennett growth while Larkin was CEO
Invisalign patients treated
22.8 million patients
Patients treated with Invisalign System over 29 years
Doctor customers
299.5 thousand doctor customers
Doctors using Align’s digital dentistry solutions
Consumer market opportunity
600 million consumers
Global consumer market opportunity cited by Align
Years in operation
29 years
Align’s history helping doctors treat patients
Key Terms
Board leadership transition, independent director, Nominating and Governance Committee, Compensation and Human Capital Committee, +1 more
5 terms
Board leadership transition financial
"ALIGN TECHNOLOGY ANNOUNCES BOARD LEADERSHIP TRANSITION."
independent director financial
"Kevin Conroy will succeed Mr. Larkin as Chairman of the Board... an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Nominating and Governance Committee financial
"Mr. Larkin will continue to serve on the Board and as a member of the Nominating and Governance Committee"
A nominating and governance committee is a group of board members tasked with choosing and evaluating directors, planning leadership succession, and setting the company’s board-related rules and ethical standards. Think of it as the company’s hiring and rule-making panel for its top overseers. Its work matters to investors because it shapes who governs the company, how leadership transitions are handled, and whether the board can effectively oversee management and protect shareholder interests.
Compensation and Human Capital Committee financial
"Chair of the Compensation and Human Capital Committee of the Board since January 2026"
A compensation and human capital committee is a board-level group that sets and oversees executive pay, employee incentive plans, hiring and retention strategies, succession planning, and workplace policies. Think of it as the company’s talent and pay steering team — it shapes who gets hired or promoted, how employees are rewarded, and how workforce risks are managed. Investors care because those choices drive labor costs, company performance, leadership stability and reputation, all of which affect long-term value.
digital orthodontics technical
"exocad CAD/CAM software for digital orthodontics and restorative dentistry"
Digital orthodontics uses digital tools—like 3D scans, computer models, treatment‑planning software and 3D‑printed or digitally manufactured aligners and appliances—to diagnose, plan and deliver teeth‑straightening care. For investors it matters because these technologies can cut treatment time and costs, enable predictable, repeatable production at scale (think replacing handmade work with factory automation), and create recurring revenue streams from devices, software and services that change how dental care is delivered.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 17, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(602 ) 742-2000
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| (NASDAQ Global Select Market) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 17, 2026, C. Raymond Larkin, Jr. notified the Board of Directors (the “Board”) of Align Technology, Inc. (the “Company”) that he will retire as Chairman of the Board effective July 1, 2026, and as a member of the Board effective December 31, 2026. Mr. Larkin’s decision to resign from the Board effective December 31, 2026 is not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, nor was he removed for cause.
Also on June 17, 2026, the Board appointed Kevin Conroy, an independent director, to succeed Mr. Larkin as Chairman of the Board, effective July 1, 2026.
Item 7.01 Regulation FD Disclosure.
On June 18, 2026, the Company issued a press release announcing the Board leadership transition and the intention of Mr. Larkin to retire from the Board effective December 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | ||||
99.1 | Press Release of Align Technology, Inc. Announcing Board Leadership Transition | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALIGN TECHNOLOGY, INC. | ||||||||
| By: | /s/ Julie Coletti | |||||||
| Julie Coletti Executive Vice President, Chief Legal and Regulatory Officer | ||||||||
Date: June 19, 2026
Exhibit 99.1
Align Technology | Zeno Group | ||||
Madelyn Valente | Sarah Karlson | ||||
(909) 833-5839 | (828) 551-4201 | ||||
mvalente@aligntech.com | sarah.karlson@zenogroup.com | ||||
ALIGN TECHNOLOGY ANNOUNCES BOARD LEADERSHIP TRANSITION.
C. RAYMOND LARKIN, JR. TO RETIRE AS CHAIRMAN AND KEVIN CONROY TO BE APPOINTED CHAIRMAN EFFECTIVE JULY 1, 2026
TEMPE, Ariz., June 18, 2026 — Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that C. Raymond Larkin, Jr. will retire as Chairman of the Board effective July 1, 2026, following more than 20 years of distinguished service on Align’s Board of Directors. Mr. Larkin will continue to serve on the Board and as a member of the Nominating and Governance Committee through December 31, 2026, to support a smooth transition.
Kevin Conroy will succeed Mr. Larkin as Chairman of the Board, effective July 1, 2026. Mr. Conroy has served as an independent director since his appointment to the Board in December 2023 and Chair of the Compensation and Human Capital Committee of the Board since January 2026.
“On behalf of the entire Board and management team, I would like to express our deep gratitude to Ray for his extraordinary leadership, partnership, and enduring contributions to Align over more than two decades,” said Joe Hogan, Align Technology president and chief executive officer. “Ray has been instrumental in guiding Align through multiple phases of growth, innovation, and scale. His strategic insight, deep experience in healthcare, and unwavering commitment to strong governance have helped shape Align into the global leader it is today.”
Mr. Hogan continued, “We are pleased to welcome Kevin as our next Chairman. Kevin brings extensive experience as a board leader and recently as CEO of Exact Sciences prior to its acquisition by Abbott Laboratories in March 2026. He has demonstrated a strong track record of creating stockholder value, and deep expertise in healthcare, technology, and strategy. His leadership will help guide Align through our next chapter of growth and innovation.”
Mr. Larkin added, “It has been an honor to serve as Chairman of Align. I am incredibly proud of all that Align has achieved and confident in its continued leadership in digital dentistry. I look forward to supporting Kevin and the Board during this transition and seeing Align continue to transform smiles and improve patient outcomes around the world well into the future.”
Mr. Conroy said, “I am honored to be appointed Chairman of Align’s Board. Align has a strong foundation, an exceptional leadership team, and significant opportunities ahead. I look forward to working closely with Joe, the Board, and management to continue driving innovation, expanding access to digital orthodontics, and creating long-term value for our stockholders.”
ABOUT C. RAYMOND LARKIN, JR.
Mr. Larkin has served as a member of Align’s Board since 2004. He has decades of leadership experience in the medical device and healthcare industries, including serving as President and Chief Executive Officer of Nellcor Puritan Bennett, where he led the company’s growth to nearly $1 billion in revenue and helped establish pulse oximetry as a global standard of care. Throughout his tenure at Align, Mr. Larkin has provided strategic guidance across periods of significant growth and innovation, drawing on his extensive public and private company board experience and deep expertise in healthcare.
ABOUT KEVIN CONROY
Mr. Conroy has served as an independent director of Align since December 2023 and Chair of the Compensation and Human Capital Committee of the Board since January 2026. He brings extensive experience as a business, legal, and strategic leader, including serving as Chairman and Chief Executive Officer of Exact Sciences Corp. until its acquisition by Abbott Laboratories in March 2026, where he led the commercialization of Cologuard and grew the company to $3.25 billion in annual revenue while serving millions of patients. Prior to Exact Sciences, Mr. Conroy served as President and CEO of Third Wave Technologies and held leadership roles at GE Healthcare. He currently serves on the board of Abbott Laboratories and brings deep expertise in healthcare innovation, strategy, and governance.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM
- 2 -
software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
- 3 -
FAQ
What Board leadership change did Align Technology (ALGN) announce?
Align Technology announced that C. Raymond Larkin, Jr. will retire as Chairman of the Board effective July 1, 2026, and remain a director until December 31, 2026. Kevin Conroy, an independent director, will succeed him as Chairman effective July 1, 2026.
Why is C. Raymond Larkin, Jr. leaving Align Technology’s Board?
The filing states that C. Raymond Larkin, Jr.’s decision to resign from Align Technology’s Board effective December 31, 2026 is not due to any disagreement with the company’s operations, policies, or practices, and that he was not removed for cause, indicating an orderly, planned transition.
Who is Kevin Conroy, the new Chairman of Align Technology (ALGN)?
Kevin Conroy is an independent director who joined Align’s Board in December 2023 and became Chair of the Compensation and Human Capital Committee in January 2026. He previously served as Chairman and CEO of Exact Sciences and currently serves on Abbott Laboratories’ board.
When will Align Technology’s Board leadership transition take effect?
The transition becomes effective July 1, 2026, when Kevin Conroy is appointed Chairman and C. Raymond Larkin, Jr. steps down from that role. Mr. Larkin will continue serving as a director and Nominating and Governance Committee member through December 31, 2026 to support continuity.
How long has C. Raymond Larkin, Jr. served on Align Technology’s Board?
C. Raymond Larkin, Jr. has served on Align Technology’s Board since 2004, providing strategic guidance through periods of significant growth and innovation. The company describes more than two decades of his leadership and experience in medical devices and healthcare as influential in shaping Align’s development.
What experience does Kevin Conroy bring to Align Technology’s Board?
Kevin Conroy brings extensive business, legal, and strategic leadership experience, including serving as Chairman and Chief Executive Officer of Exact Sciences Corp. until its acquisition by Abbott Laboratories in March 2026. At Exact Sciences he helped commercialize Cologuard and grew the company to $3.25 billion in annual revenue.